Adia Nutrition Inc. Takes Major Steps Forward: Signs LOI for First Clinic and Engages Legal Expertise for Licensing
Adia Nutrition (OTC Pink: ADIA) has announced significant progress in its Multiple Sclerosis (MS) treatment initiative. The company has signed a Letter of Intent (LOI) to lease a clinic in Winter Park, Florida, which will offer Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for MS patients. This development is ahead of the company's initial expansion projections.
To ensure regulatory compliance, Adia Nutrition has engaged the law firm Smith Hulsey & Busey, with attorney Jeanne Helton leading efforts to secure necessary medical licenses and uphold patient care standards. The Winter Park clinic will feature state-of-the-art facilities, representing a significant step forward in personalized healthcare for MS treatment.
Adia Nutrition (OTC Pink: ADIA) ha annunciato progressi significativi nella sua iniziativa di trattamento della Sclerosi Multipla (SM). L'azienda ha firmato una Lettera di Intenti (LOI) per affittare una clinica a Winter Park, Florida, che offrirà Trapianti Autologhi di Cellule Staminali Ematopoietiche (AHSCT) per i pazienti con SM. Questo sviluppo è in anticipo rispetto alle proiezioni iniziali di espansione dell'azienda.
Per garantire la conformità normativa, Adia Nutrition ha stabilito un incarico con lo studio legale Smith Hulsey & Busey, con l'avvocato Jeanne Helton a capo degli sforzi per ottenere le necessarie licenze mediche e mantenere gli standard di assistenza ai pazienti. La clinica di Winter Park disporrà di strutture all'avanguardia, rappresentando un passo significativo verso la sanità personalizzata per il trattamento della SM.
Adia Nutrition (OTC Pink: ADIA) ha anunciado avances significativos en su iniciativa de tratamiento de la Esclerosis Múltiple (EM). La compañía ha firmado una Carta de Intención (LOI) para arrendar una clínica en Winter Park, Florida, que ofrecerá Transplante Autólogo de Células Madre Hematopoyéticas (AHSCT) para pacientes con EM. Este desarrollo es anticipado en comparación con las proyecciones iniciales de expansión de la compañía.
Para asegurar el cumplimiento normativo, Adia Nutrition ha contratado al bufete de abogados Smith Hulsey & Busey, con la abogada Jeanne Helton liderando los esfuerzos para obtener las licencias médicas necesarias y mantener los estándares de atención al paciente. La clínica de Winter Park contará con instalaciones de última generación, representando un paso significativo hacia la atención médica personalizada para el tratamiento de la EM.
아디아 뉴트리션 (OTC Pink: ADIA)은 다발성 경화증 (MS) 치료 사업에서 중요한 진전을 발표했습니다. 회사는 플로리다주 윈터 파크에서 클리닉을 임대하기 위한 의향서 (LOI)에 서명했습니다, 이 클리닉은 MS 환자를 위한 자가 조혈 줄기 세포 이식 (AHSCT)을 제공할 것입니다. 이 개발은 회사의 초기 확장 예측보다 앞서 있습니다.
규제 준수를 보장하기 위해, 아디아 뉴트리션은 스미스 헐시 & 뷰시 법률 사무소를 고용했습니다, 변호사 진 헬튼이 필요한 의료 면허를 확보하고 환자 관리 기준을 유지하기 위한 노력을 이끌고 있습니다. 윈터 파크 클리닉은 최신 시설을 갖추게 되며, MS 치료를 위한 개인 맞춤형 의료로 나아가는 중요한 단계입니다.
Adia Nutrition (OTC Pink: ADIA) a annoncé des progrès significatifs dans son initiative de traitement de la sclérose en plaques (SEP). L'entreprise a signé une Lettre d'Intention (LOI) pour louer une clinique à Winter Park, en Floride, qui proposera une Transplantation Autologue de Cellules Souches Hématopoïétiques (AHSCT) pour les patients atteints de SEP. Ce développement est en avance sur les projections d'expansion initiales de l'entreprise.
Pour garantir la conformité réglementaire, Adia Nutrition a engagé le cabinet d'avocats Smith Hulsey & Busey, avec l'avocate Jeanne Helton dirigeant les efforts pour obtenir les licences médicales nécessaires et maintenir les normes de soins aux patients. La clinique de Winter Park sera dotée d'installations à la pointe de la technologie, représentant un pas significatif vers des soins de santé personnalisés pour le traitement de la SEP.
Adia Nutrition (OTC Pink: ADIA) hat bedeutende Fortschritte in seiner Initiative zur Behandlung der Multiplen Sklerose (MS) bekannt gegeben. Das Unternehmen hat einen Letter of Intent (LOI) zur Anmietung einer Klinik in Winter Park, Florida, unterzeichnet, die autologe hämatopoetische Stammzelltransplantation (AHSCT) für MS-Patienten anbieten wird. Diese Entwicklung ist früher als die ursprünglichen Expansionsprognosen des Unternehmens.
Um die regulatorischen Anforderungen zu erfüllen, hat Adia Nutrition die Kanzlei Smith Hulsey & Busey beauftragt, wobei Anwältin Jeanne Helton die Bemühungen leitet, die erforderlichen medizinischen Lizenzen zu sichern und die Patientenversorgungsstandards aufrechtzuerhalten. Die Klinik in Winter Park wird mit modernsten Einrichtungen ausgestattet sein, was einen bedeutenden Schritt in der personalisierten Gesundheitsversorgung für die MS-Behandlung darstellt.
- Signed LOI for a new clinic in Winter Park, Florida, ahead of initial expansion projections
- Clinic will offer advanced Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for MS treatment
- Engaged legal expertise to navigate medical licensing and regulatory compliance
- None.
WINTER PARK, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is proud to announce a groundbreaking initiative in the fight against Multiple Sclerosis (MS) with the signing of a Letter of Intent (LOI) to lease a new clinic in Winter Park, Florida. The clinic, which will offer Autologous Hematopoietic Stem Cell Transplantation (AHSCT) specifically for MS treatment, represents a significant leap forward in personalized health care, well ahead of the company's initial expansion projections.
The lease agreement for this innovative facility is expected to be finalized within the next week, emphasizing Adia Nutrition's accelerated pace in bringing advanced treatments closer to those in need.
To navigate the complex landscape of medical licensing and regulatory compliance, Adia Nutrition has enlisted the expertise of the law firm Smith Hulsey & Busey. Attorney Jeanne Helton will lead the firm's efforts to ensure Adia Nutrition's clinic operates within all local, state, and federal regulations, securing the necessary medical licenses and upholding the highest standards of patient care and safety.
"We are incredibly excited about this venture into MS treatment through AHSCT," stated Larry Powalisz, CEO of Adia Nutrition. "Being able to offer this advanced treatment option ahead of schedule is a testament to our team's dedication and the support from our community. Partnering with Smith Hulsey & Busey, particularly with Jeanne Helton, who has expertise in dealing with health regulatory bodies including the FDA, ensures we adhere to the rigorous standards required in healthcare, providing peace of mind for our patients and stakeholders."
The Winter Park clinic will feature state-of-the-art facilities designed to give hope and innovative care to MS patients, offering a beacon of progress in the treatment landscape. Adia Nutrition remains committed to pushing the boundaries of what's possible in health care, with a focus on personalized, effective treatments.
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adia-med.com
Website: www.biolete.com
Website: www.cementfactory.com
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
FAQ
What is Adia Nutrition's (ADIA) latest development in MS treatment?
How is Adia Nutrition (ADIA) ensuring regulatory compliance for its new clinic?
What treatment will Adia Nutrition's (ADIA) new clinic in Winter Park offer?
When is the lease agreement for Adia Nutrition's (ADIA) new clinic expected to be finalized?
